The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Separating everolimus- and more generally mTOR inhibitor-induced ILD in lung transplant recipients from rejection can be challenging (PMID 29713487)

Publications

Saito Y, Terasaki Y, Kashiwada T, Tanaka T, Takei H, Kimura G, Kondo Y, Kawagoe T, Matsushita A, Noro R, Minegishi Y, Kamio K, Seike M, Gemma A

Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 2024;91(2):207-217

Kim CJ, McKenzie D, Joseph JK, Aytaman Y, Lam ML, Soni L, McFarlane SI

Refractory Metastatic Insulinoma Treated with Everolimus, Complicated by Cryptogenic Organizing Pneumonia.

American journal of medical case reports 2019;7;125-132

Willemsen AECAB, Tol J, van Erp NP, Jonker MA, de Boer M, Meek B, de Jong PC, van Moorsel C, Gerritsen WR, Grutters JC, van Herpen CML

Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.

Targeted oncology. 2019;14(4):441-451

Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J

mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.

International journal of cancer. 2016;138(10):2312-21

Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, Cheng Y, Khindri S, Kovarik JM, Ma S, McCormack FX, Henske EP

Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.

The European respiratory journal. 2015;46(3):783-94

Park K, Kim HJ, Lee JL, Lee KH, Jeong IG, Song C, Hong BS, Hong J, Kim CS, Ahn H

Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.

Anticancer research. 2014;34(10):5723-8

Baas MC, Struijk GH, Moes DJ, van den Berk IA, Jonkers RE, de Fijter JW, van der Heide JJ, van Dijk M, ten Berge IJ, Bemelman FJ

Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients.

Transplant international : official journal of the European Society for Organ Transplantation. 2014;27(5):428-36

Amato R, Stepankiw M

Evaluation of everolimus in renal cell cancer.

Expert opinion on pharmacotherapy. 2013;14(9):1229-40

Sułkowska K, Palczewski P, Miszewska-Szyszkowska D, Durlik M, Gołębiowski M, Małkowski P

Early everolimus-induced pneumonitis in a renal transplant recipient: A case report.

Annals of transplantation. 2012;17(4):144-8

Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T, RADIANT-2 Study Group

Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.

The oncologist. 2013;18(1):46-53

Sakamoto S, Kikuchi N, Ichikawa A, Sano G, Satoh K, Sugino K, Isobe K, Takai Y, Shibuya K, Homma S

Everolimus-induced pneumonitis after drug-eluting stent implantation: a case report.

Cardiovascular and interventional radiology. 2013;36(4):1151-4

Mizuno R, Asano K, Mikami S, Nagata H, Kaneko G, Oya M

Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.

Japanese journal of clinical oncology. 2012;42(5):442-6

White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.

American journal of respiratory and critical care medicine. 2010;182(3):396-403

White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH

Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009;4(11):1357-63

Aparicio G, Calvo MB, Medina V, Fernández O, Jiménez P, Lema M, Figueroa A, Antón Aparicio LM

Comprehensive lung injury pathology induced by mTOR inhibitors.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2009;11(8):499-510

Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology. 2009;20(10):1674-81

Schrader J, Sterneck M, Klose H, Lohse AW, Nashan B, Fischer L

Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options.

Transplant international : official journal of the European Society for Organ Transplantation. 2010;23(1):110-3

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1 Study Group

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Lancet (London, England). 2008;372(9637):449-56

Expósito V, de Prada JA, Gómez-Román JJ, González-Vilchez F, Llano-Cardenal M, García-Camarero T, Fernández-Valls M, Ruano J, Martín-Durán R

Everolimus-related pulmonary toxicity in heart transplant recipients.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2008;27(7):797-800